HCWB

Insider Trades

Name	Value	Action	Price	Current Price
Garrett Scott TDirector $250k177.9k shares BuyMay 22, 2026 $1.41 --
Garrett Scott TDirector $228k177.9k shares BuyMay 22, 2026 $1.28 --
Wong Hing CDirector, 10 Percent Owner, Officer: Chief Executive Officer $160k113.9k shares BuyMay 22, 2026 $1.41 --
Wong Hing CDirector, 10 Percent Owner, Officer: Chief Executive Officer $146k113.9k shares BuyMay 22, 2026 $1.28 --
Byam RebeccaChief Financial Officer $20k14.2k shares BuyMay 22, 2026 $1.41 --
Byam RebeccaChief Financial Officer $18k14.2k shares BuyMay 22, 2026 $1.28 --

News

benzinga.comMicrocap HCW Biologics' Therapy Shows Early Promise Against Autoimmune Hair Lossbenzinga.comJun 16

globenewswire.comHCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areataglobenewswire.comJun 16

globenewswire.comHCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugenglobenewswire.comMay 27

globenewswire.comE.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placementglobenewswire.comMay 22

globenewswire.comHCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rulesglobenewswire.comMay 21

Trade HCWB

About HCW Biologics Inc.

HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.

CEO: Hing C. Wong
IPO Date: Jul 20, 2021

Market Data

Open: $1.09
High: $1.13
Low: $1.04
Volume: 928.8K
Avg Volume: 12.7M
52W High: $7.35
52W Low: $0.25

Valuation

Market Cap: $2.3M
Enterprise Value: $7.6M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-13M
Revenue: $54k
Net Income: $-8.0M
Cash: $2.0M
Debt: $6.8M

Events

EarningsAug 7

EPS est. -0.33